Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 4/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.40 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.40 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6416439 | 0.99 | HCRTR2 (0.43) | HCRTR2POLBROCK2ROCK1CCR5 | |
| SCHEMBL6409016 | 0.91 | HCRTR2 (0.43) | HCRTR2ROCK2ROCK1CCR5CHRM1 | |
| SCHEMBL6409501 | 0.91 | HCRTR2 (0.43) | HCRTR2ROCK2ROCK1CCR5CHRM1 | |
| SCHEMBL6417255 | 0.91 | GPR88 (0.45) | HCRTR2ROCK2ROCK1CCR5CHRM1 | |
| SCHEMBL6409967 | 0.91 | GPR88 (0.45) | HCRTR2ROCK2ROCK1CCR5CHRM1 | |
| Hydrochloric Acid SCHEMBL6410988 | 0.91 | HCRTR2 (0.42) | HCRTR2ROCK2ROCK1CCR5CHRM1 | |
| SCHEMBL6409973 | 0.91 | GPR88 (0.45) | HCRTR2ROCK2ROCK1CCR5CHRM1 | |
| SCHEMBL6410424 | 0.90 | ROCK2 (0.52) | HCRTR2ROCK2ROCK1CCR5 | |
| SCHEMBL6409327 | 0.90 | HCRTR2 (0.43) | HCRTR2ROCK2ROCK1CCR5ALDH1A1 | |
| SCHEMBL6412968 | 0.90 | HCRTR2 (0.44) | HCRTR2POLBROCK2ROCK1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA INC (CA) | 2005-04-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | CXCR1, CXCR4, CXCR2 | HCRTR2 247/4885POLB 3564/4885ROCK2 1735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.